Abstract:Abstract Introduction: Myelodysplastic syndrome (MDS) represents a heterogeneous group of hematopoietic stem cell disorders characterized by single-lineage or multi-lineage cytopenias and a risk of progression to acute myeloid leukemia (AML). Despite the development of new drugs, allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only potential curative therapy. We have a retrospective analysis of the efficacy and security of the allo-HSCT therapy for MDS in our singal centre. Method: Between June1999 and March 2012, 39 MDS patients with a median age of 32 years (range, 12-52) were transplanted with a matched related donor (n=10), unrelated donor (n=20) or haploidentical donor (n=9) in our centre. Of the patients, 62% were male; 44% had intermediate-1 risk, 13% intermediate-2 risk and 43% poor risk cytogenetics by the International Prognostic Scoring System criteria. The cell source was bone marrow (BM) in 36%, peripheral blood (PB) in 59% and BM+PB in 5%. 51% patients had received chemotherapy prior HSCT. Conditioning regimens were BUCY or BUCY plus ATG for matched related HSCT and unrelated transplants, AraC+BuCy+ATG+MeCCNU for haploidentical transplants. The median number of CD34+ cells/kg infusion was 5.52×106(range, 0.8×106-10.38×106).Graft-versus-host disease prophylaxis was employed by cyclosporine A (CsA), mycophenolate mofetil (MMF) and short-term methotrexate (MTX). 25 patients received serum ferritin measurement berore HSCT. The mediun level of serum ferritin was 1100ng/ml (range, 456-2318). Result: The median follow-up was 27 months(range,1.5-154). The 3-year disease free survival(DFS) was 60.8%. Transplant related mortality(TRM) was assessed at 37% on the whole cohort. 5% has no engraftment for a total of 2 patients. A neutrophil count of >0.5 × 109/L was achieved at a median of 12 days (range, 9–24 days) and a platelet count of >20 × 109/L within 14 days (9–49 days) post-transplant. Acute GVDH grade 1-2 was documented in 49%, grade 3-4 in 5% and no GVDH in 46%. Chronic GVHD could be identified in 27 patients (69%), 5 of whom had extensive disease, while the other 22 had limited disease. Overall 14 patients (36%) died. Causes of death were Infection 57%,GVDH 8%, haemorrhage 14%, engraft failure 14% and “other causes” 7%. Only one patients died because of relapse of the disease.DFS according to donor source (matched related donor 87.5%, unrelated donor 51.6% and haploidentical donor 55.6%) was not significant (p =0.22 ). Likewise no significant difference was found on DFS among BM 57%, PB 66.4% and BM+PB 50% (p =0.65). A similar DFS was seen in different risk categories (56.7% in intermediate, 66.7% in high-risk; p=0.51). No difference was seen in DFS according to the CD34+ cell number and whether received chemotherapy prior to HSCT. Only the elevated serum ferritin is associated with inferior DFS after HSCT(p =0.018 ). Disclosures No relevant conflicts of interest to declare.

Clinical Significance of Serum Ferritin at Diagnosis in Patients With Acute Myeloid Leukemia: A YACHT Multicenter Retrospective Study

Serem Ferritin Was the Only Prognostic Factor for Disease Free Survival in Mds Patients after Allo-Hsct: A Single Centre Study

Iron Metabolism Before Allo-Hsct in Patients with Acute Leukemia and Impact of Iron Overload on Transplantation

Elevated Serum Ferritin Levels Are Associated with Severity and Prognosis of Severe Acute Pancreatitis: a Preliminary Cohort Study

A Meta-Analysis for Effects of Elevated Pre-Transplantation Serum Ferritin on the Outcomes in Patients Undergoing Hematopoietic Stem Cell Transplantation.

Prevalence and Severity of Thrombocytopenia in Patients with Hyperferritinemia

A Novel Ferroptosis-Related Gene Signature Can Predict Prognosis and Influence Immune Microenvironment in Acute Myeloid Leukemia.

Impact of Serum Ferritin and Iron Overload on Acute Myeloid Leukemia Outcomes: A Systematic Review and Meta-Analysis

Factors Affecting Early Death and Survival of Patients with Acute Promyelocytic Leukemia Treated with ATRA-Based Therapy Regimens

Serum Ferritin Increased the Predictive Value of the International Staging System/Revised International Staging System for Overall Survival

Strength in Numbers - Identifying a Significant Association Between High Serum Ferritin Levels and Newly diagnosed Malignancy in a Large Health Organization Cohort

Is Serum Ferritin a Predictor of Blood Transfusions Outcome and Survival in Childhood Lymphomas and Solid Tumors?

Can Serum Ferritin Serve As a Biomarker for the Prognosis of Gynecological Malignant Tumors? A Retrospective Cohort Study.

Ferritin/alanine aminotransferase ratio as a possible marker for predicting the prognosis of acute liver injury

Serum ferritin levels in previously untreated classical Hodgkin lymphoma: correlations and prognostic significance

The Impact of Pretransplant Serum Ferritin on Haploidentical Hematopoietic Stem Cell Transplant for Acquired Severe Aplastic Anemia in Children and Adolescents

Iron Overload in Children with Acute Lymphoblastic and Acute Myeloblastic Leukemia—Experience of One Center

Ferritin as an early marker of graft rejection after allogeneic hematopoietic stem cell transplantation in pediatric patients

Serum Ferritin Is a Clinical Biomarker in Japanese Patients with Nonalcoholic Steatohepatitis (NASH) Independent of HFE Gene Mutation

Association of serum ferritin and all-cause mortality in AKI patients: a retrospective cohort study

Ferritin, inflammation, and iron deficiency in acute heart failure: evidence from the EDIFICA cohort